Kanamycin Sulfate Powder - China

Kanamycin sulfate powder

COMPOSITION

Each 1g contains Kanamycin 120mg

INDICATIONS

For the treatment intestinal infection caused by chicken susceptible bacteria.

DOSAGE AND ADMINISTRATION

By oral administration via drinking water.

Calculated on Kanamycin.

Chicken: 60-120mg mixed with 1 liter water.

ADVERSE RACTION

Renal toxicity, ototoxicity and neuromuscular blocking effect, combined with diuretics, erythromycin may enhance the toxicity of this class of drugs.

Ca2+, Mg2+, Na+, NH4+, K+ and other cations can inhibit the antibacterial activity of amino acid glycosides, drug sensitivity test should pay attention to control the cation concentration in the medium

SPECIAL WARNINGS

This product and aminoglycoside drugs have cross-resistance.

WITHDRAWAL PERIOD

Chicken: 28 days

Eggs: 7 days

STORAGE

Seal and store in a dry place.

Keep out of reach of children.

PACKAGING

100g/150g/500g/1000g/b ag

SHELF LIFE

3 years.

Company Contact:

• Posted By: Shijiazhuang Shimu Animal Pharmaceutical Co., Ltd.

• Phone: 86 311 67267356

• Address: Room 1105, Zone B, Jinyuan Business Office Building, Huaian East Road, Yuhua District, Shijiazhuang , Shijiazhuang , Hebei , China

• Email:

• Website: https://www.skyvetpharm.com/

• Business Description: Shimu group was founded in 2001, located in Shijiazhuang high-tech industrial zone, including Shijiazhuang Shimu Animal Pharmaceutical Co., Ltd, Hebei Tianqiong International Trade Co., Ltd, Hebei Huamu Tianhe Biological technology Co., Ltd, three pillar industries.
  
  Shimu group is a comprehensive high-tech enterprise specialized in R&D, production, marketing and technical service.
  
  The first phase project was completed in 2005, and got the GMP certification successfully.
  
  So far we have 6 production line, including powder, premix, pulvis, oral solution, disinfectant, insecticide.
  
  In 2012, Shimu passed GMP inspection routinely by China Ministry of Agriculture.
  
  For now the second phase project is under construction, the tablet, granules, injection, powder for injection, intramammary infusion will bring into production in June, 2018.